Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19.

ABSTRACT:

Importance

COVID-19 is a life-threatening illness for many patients. Prior studies have established hematologic cancers as a risk factor associated with particularly poor outcomes from COVID-19. To our knowledge, no studies have established a beneficial role for anti-COVID-19 interventions in this at-risk population. Convalescent plasma therapy may benefit immunocompromised individuals with COVID-19, including those with hematologic cancers.

Objective

To evaluate the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic cancers and COVID-19 from a multi-institutional cohort.

Design, setting, and participants

This retrospective cohort study using data from the COVID-19 and Cancer Consortium registry with propensity s

SUBMITTER: Thompson MA 

PROVIDER: S-EPMC8377563 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature